Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: a meta-analysis

Miriam A. Schiele; Andreas Reif; Jiaxi Lin; Georg W. Alpers; Evelyn Andersson; Gerhard Andersson; Volker Arolt; Jan Bergström; Per Carlbring; Thalia C. Eley; Gabriel Esquivel; Tomas Furmark; Alexander L. Gerlach; Alfons Hamm; Sylvia Helbig-Lang; Jennifer L. Hudson; Thomas Lang; Kathryn J. Lester; Nils Lindefors; Tina B. Lonsdorf; Paul Pauli; Jan Richter; Winfried Rief; Susanna Roberts; Christian Rück; Koen R. J. Schruers; Christiane Thiel; Hans Ulrich Wittchen; Katharina Domschke; Heike Weber; Ulrike Lueken

doi:10.1016/j.euroneuro.2021.01.004

Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: a meta-analysis

Miriam A. Schiele^*, Andreas Reif, Jiaxi Lin, Georg W. Alpers, Evelyn Andersson, Gerhard Andersson, Volker Arolt, Jan Bergström, Per Carlbring, Thalia C. Eley, Gabriel Esquivel, Tomas Furmark, Alexander L. Gerlach, Alfons Hamm, Sylvia Helbig-Lang, Jennifer L. Hudson, Thomas Lang, Kathryn J. Lester, Nils Lindefors, Tina B. LonsdorfPaul Pauli, Jan Richter, Winfried Rief, Susanna Roberts, Christian Rück, Koen R. J. Schruers, Christiane Thiel, Hans Ulrich Wittchen, Katharina Domschke, Heike Weber, Ulrike Lueken

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

17 Downloads (Pure)

Abstract

There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.

Original language	English
Pages (from-to)	105-120
Number of pages	16
Journal	European Neuropsychopharmacology
Volume	44
DOIs	https://doi.org/10.1016/j.euroneuro.2021.01.004
Publication status	Published - Mar 2021

Keywords

serotonin transporter gene
therapygenetics
treatment response
therapy outcome
CBT
panic disorder

Access to Document

10.1016/j.euroneuro.2021.01.004

Accepted author manuscriptAccepted author manuscript, 885 KBLicence: CC BY-NC-ND

Cite this

Schiele, M. A., Reif, A., Lin, J., Alpers, G. W., Andersson, E., Andersson, G., Arolt, V., Bergström, J., Carlbring, P., Eley, T. C., Esquivel, G., Furmark, T., Gerlach, A. L., Hamm, A., Helbig-Lang, S., Hudson, J. L., Lang, T., Lester, K. J., Lindefors, N., ... Lueken, U. (2021). Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: a meta-analysis. European Neuropsychopharmacology, 44, 105-120. https://doi.org/10.1016/j.euroneuro.2021.01.004

@article{af506f84791744948e94895429548daa,

title = "Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: a meta-analysis",

abstract = "There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.",

keywords = "serotonin transporter gene, therapygenetics, treatment response, therapy outcome, CBT, panic disorder",

author = "Schiele, {Miriam A.} and Andreas Reif and Jiaxi Lin and Alpers, {Georg W.} and Evelyn Andersson and Gerhard Andersson and Volker Arolt and Jan Bergstr{\"o}m and Per Carlbring and Eley, {Thalia C.} and Gabriel Esquivel and Tomas Furmark and Gerlach, {Alexander L.} and Alfons Hamm and Sylvia Helbig-Lang and Hudson, {Jennifer L.} and Thomas Lang and Lester, {Kathryn J.} and Nils Lindefors and Lonsdorf, {Tina B.} and Paul Pauli and Jan Richter and Winfried Rief and Susanna Roberts and Christian R{\"u}ck and Schruers, {Koen R. J.} and Christiane Thiel and Wittchen, {Hans Ulrich} and Katharina Domschke and Heike Weber and Ulrike Lueken",

year = "2021",

month = mar,

doi = "10.1016/j.euroneuro.2021.01.004",

language = "English",

volume = "44",

pages = "105--120",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

}

Schiele, MA, Reif, A, Lin, J, Alpers, GW, Andersson, E, Andersson, G, Arolt, V, Bergström, J, Carlbring, P, Eley, TC, Esquivel, G, Furmark, T, Gerlach, AL, Hamm, A, Helbig-Lang, S, Hudson, JL, Lang, T, Lester, KJ, Lindefors, N, Lonsdorf, TB, Pauli, P, Richter, J, Rief, W, Roberts, S, Rück, C, Schruers, KRJ, Thiel, C, Wittchen, HU, Domschke, K, Weber, H & Lueken, U 2021, 'Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: a meta-analysis', European Neuropsychopharmacology, vol. 44, pp. 105-120. https://doi.org/10.1016/j.euroneuro.2021.01.004

TY - JOUR

T1 - Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders

T2 - a meta-analysis

AU - Schiele, Miriam A.

AU - Reif, Andreas

AU - Lin, Jiaxi

AU - Alpers, Georg W.

AU - Andersson, Evelyn

AU - Andersson, Gerhard

AU - Arolt, Volker

AU - Bergström, Jan

AU - Carlbring, Per

AU - Eley, Thalia C.

AU - Esquivel, Gabriel

AU - Furmark, Tomas

AU - Gerlach, Alexander L.

AU - Hamm, Alfons

AU - Helbig-Lang, Sylvia

AU - Hudson, Jennifer L.

AU - Lang, Thomas

AU - Lester, Kathryn J.

AU - Lindefors, Nils

AU - Lonsdorf, Tina B.

AU - Pauli, Paul

AU - Richter, Jan

AU - Rief, Winfried

AU - Roberts, Susanna

AU - Rück, Christian

AU - Schruers, Koen R. J.

AU - Thiel, Christiane

AU - Wittchen, Hans Ulrich

AU - Domschke, Katharina

AU - Weber, Heike

AU - Lueken, Ulrike

PY - 2021/3

Y1 - 2021/3

N2 - There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.

AB - There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy.

KW - serotonin transporter gene

KW - therapygenetics

KW - treatment response

KW - therapy outcome

KW - CBT

KW - panic disorder

UR - http://www.scopus.com/inward/record.url?scp=85099635301&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2021.01.004

DO - 10.1016/j.euroneuro.2021.01.004

M3 - Article

C2 - 33483252

AN - SCOPUS:85099635301

SN - 0924-977X

VL - 44

SP - 105

EP - 120

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

ER -

Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: a meta-analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this